Skip to main content
SpringerLink
Log in

Present Situation and Prospect of Diagnosis and Treatment of Colorectal Cancer

  • Chapter
  • First Online:
Multidisciplinary Management of Liver Metastases in Colorectal Cancer

  • 973 Accesses

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumors. The probability of suffering from colorectal cancer in a person’s life is 6 %. There are about 1.20 million new colorectal cancer cases in the world each year. Nearly 600,000 people die of colorectal cancer each year. Among all malignant tumors, both incidence and mortality of colorectal cancer are in the third position. In recent years, incidence and mortality of colorectal cancer in western-developed countries have decreased a little, whereas incidence of colorectal cancer in developing countries has still showed a rising trend [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sung JJ, Lau JY, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 2008;57:1166–6.

    Article  CAS  PubMed  Google Scholar 

  2. Lin C, Yang B, Donald M, et al. Cancer trends in Asian Pacific Rim Region. Tumor. 2004;24:422–6.

    Google Scholar 

  3. You WC, Jin F, Devesa S, et al. Rapid increase in colorectal cancer rates in urban Shanghai, 1972–97, in relation to dietary changes. J Cancer Epidemiol Prev. 2002;7:143–6.

    PubMed  Google Scholar 

  4. Pfister DG, Benson AB, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350:2375–2.

    Article  CAS  PubMed  Google Scholar 

  5. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378–1.

    Article  PubMed  Google Scholar 

  6. Shu Z, Hai Y, Gong Y, et al. Optimization of sequential screening scheme for colorectal cancer. Chinese Tumor. 1994;3:15–6.

    Google Scholar 

  7. Shinya H, Wolff WI. Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg. 1979;190:679–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008;88:819–4.

    Article  PubMed  Google Scholar 

  9. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112:24–8.

    Article  CAS  PubMed  Google Scholar 

  10. Mak T, Lalloo F, Evans DG, Hill J. Molecular stool screening for colorectal cancer. Br J Surg. 2004;91:790.

    Article  CAS  PubMed  Google Scholar 

  11. Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA. 2004;291:1713–9.

    Article  CAS  PubMed  Google Scholar 

  12. Jianping W, Zuli Y, Yuanzhi T, et al. Effects of pelvic autonomic nerve preservation on male patients with rectal cancer. Chin J Pract Surg. 2003;23:44–6.

    Google Scholar 

  13. Jianping W, Huang M, Xinming S, et al. The assessment of curative effect after total mesorectal excision with autonomic nerve preservation for rectal cancer. Chin J Surg. 2005;43:1500–2.

    Google Scholar 

  14. Jianping W, Jun Z, Xinming S, et al. Analysis on pelvic autonomic nerve preservation in 120 female patients of rectal carcinoma undergoing radical resection. Chin J Gen Surg. 2005;20:619–21.

    Google Scholar 

  15. Jianping W, Guanfu C, Meijin H, et al. Influence of surgeon-related factors on postoperative sexual function in patients with rectal cancer. Chin J Pract Surg. 2005;25:688–9.

    Google Scholar 

  16. Ce Z, Zihai D, Guoxin L, et al. Anatomical observations of pelvic autonomic nerves concerning with total mesorectal excision. Chin J Clin Anat. 2006;24:60–4.

    Google Scholar 

  17. Willett CG, Compton CC, Shellito PC, Efird JT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer. 1994;73:2716–20.

    Article  CAS  PubMed  Google Scholar 

  18. Greenberg JA, Shibata D, Herndon JE, et al. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008;51:1185–4.

    Article  PubMed  Google Scholar 

  19. Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236:522–30.

    Article  PubMed  PubMed Central  Google Scholar 

  20. McCall JL. Total mesorectal excision: evaluating the evidence. Aust N Z J Surg. 1997;67:599–2.

    Article  CAS  PubMed  Google Scholar 

  21. Kockerling F, Reymond MA, Altendorf-Hofmann A, et al. Influence of surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol. 1998;16:324–9.

    CAS  PubMed  Google Scholar 

  22. Heald RJ, Smedh RK, Kald A, et al. Abdominoperineal excision of the rectum – an endangered operation. Norman Nigro Lectureship. Dis Colon Rectum. 1997;40:747–1.

    Article  CAS  PubMed  Google Scholar 

  23. Carlsen E, Schlichting E, Guldvog I, et al. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg. 1998;85:526–9.

    Article  CAS  PubMed  Google Scholar 

  24. Law WL, Chu KW. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg. 2004;240:260–8.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356:93–6.

    Article  CAS  PubMed  Google Scholar 

  26. Martling A, Cedermark B, Johansson H, et al. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg. 2002;89:1008–3.

    Article  CAS  PubMed  Google Scholar 

  27. Martling A, Holm T, Rutqvist LE, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg. 2005;92:225–9.

    Article  CAS  PubMed  Google Scholar 

  28. Takahashi T, Ueno M, Azekura K, Ohta H. Lateral node dissection and total mesorectal excision for rectal cancer. Dis Colon Rectum. 2000;43:59–8.

    Article  Google Scholar 

  29. Xinshu D, Zhigao L, Binbin C, et al. Clinical significance of lateral lymphadenectomy in lower rectal cancer therapy. Chin J Bases Clin Gen Surg. 2003;10:103–4.

    Google Scholar 

  30. Grinnell RS. Lymphatic block with atypical and retrograde lymphatic metastasis and spread in carcinoma of the colon and rectum. Ann Surg. 1966;163:272–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg. 2008;95:33–9.

    Article  CAS  PubMed  Google Scholar 

  32. Xinshu D, Haitao X, Zhigao L, et al. Effect of lateral lymph nodes dissection and autonomic nerve preservation in anterior resection for rectal cancer: 124 cases review. Chin J Surg. 2007;45:1164–6.

    Google Scholar 

  33. Wan Y, Pan Y, Yucun L, et al. Patterns of lymph node metastasis and extent of lymph node dissection for middle or lower rectal cancer: analysis of 462. Chin J Surg. 2001;39:425–8.

    Google Scholar 

  34. Wan Y, Pan Y, Yucun L, et al. The characteristics of lateral node metastasis in middle/lower rectal cancer and its influence on the prognosis. Chin J Gastrointest Surg. 2004;7:104–6.

    Google Scholar 

  35. Fleshman JW, Nelson H, Peters WR, et al. Early results of laparoscopic surgery for colorectal cancer. Retrospective analysis of 372 patients treated by Clinical Outcomes of Surgical Therapy (COST) Study Group. Dis Colon Rectum. 1996;39:53–8.

    Article  Google Scholar 

  36. Nelson H, Sargent D, Wieand H, et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–9.

    Article  CAS  Google Scholar 

  37. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005;6:477–4.

    Article  PubMed  Google Scholar 

  38. Buunen M, Veldkamp R, Hop WC, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 2009;10:44–2.

    Article  PubMed  Google Scholar 

  39. Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–8.

    Article  PubMed  Google Scholar 

  40. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.

    Article  PubMed  Google Scholar 

  41. Abraham NS, Young JM, Solomon MJ. Meta-analysis of short-term outcomes after laparoscopic resection for colorectal cancer. Br J Surg. 2004;91:1111–4.

    Article  CAS  PubMed  Google Scholar 

  42. Guillou P, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718–6.

    Article  PubMed  Google Scholar 

  43. Leroy J, Jamali F, Forbes L, et al. Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes. Surg Endosc. 2004;18:281–9.

    Article  CAS  PubMed  Google Scholar 

  44. Minhua Z, Yanyan H, Aiguo L, et al. Clinical comparison of laparoscopic and open total mesorectal excision for lower rectal cancer. Chin J Gastrointest Surg. 2004;7:177–80.

    Google Scholar 

  45. Mei H, Zongguang Z, Wenzhang L, et al. Laparoscopic versus open total mesorectal excision with anal sphincter preservation for low rectal cancer: a randomized trial on short-term outcomes. Chin J Gastrointest Surg. 2003;6:368–71.

    Google Scholar 

  46. Lochan R, White SA, Manas DM. Liver resection for colorectal liver metastasis. Surg Oncol. 2007;16:33–5.

    Article  CAS  PubMed  Google Scholar 

  47. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003;12:165–2.

    Article  PubMed  Google Scholar 

  48. Bengtsson G, Carlsson G, Hafstrom L, et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586–9.

    Article  CAS  PubMed  Google Scholar 

  49. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Nagakura S, Shirai Y, Yokoyama N, et al. Major hepatic resection reduces the probability of intrahepatic recurrences following resection of colorectal carcinoma liver metastases. Hepatogastroenterology. 2003;50:779–3.

    PubMed  Google Scholar 

  51. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221:159–6.

    Article  CAS  PubMed  Google Scholar 

  52. Desen W. Adjuvant chemotherapy and neoadjuvant chemotherapy for colorectal cancer. In: Desen W, editor. Colorectal cancer. Beijing, China: Peking University Medical Press; p. 203–20.

    Google Scholar 

  53. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11:1879–7.

    CAS  PubMed  Google Scholar 

  54. Haller D, Catalano P, Macdonald J, et al. Fluorouracil (FU), leucovorin and levamisole adjuvant therapy for colon cancer: five year report of INT-0089. Proc Am Soc Clin Oncol. 1998;17:256a.

    Google Scholar 

  55. Wolmark N, Colangelo L, Wieand S. National surgical adjuvant breast and bowel project trials in colon cancer. Semin Oncol. 2001;28:9–3.

    Article  CAS  PubMed  Google Scholar 

  56. O’Connell MJ. North Central Cancer Treatment Group – Mayo Clinic trials in colon cancer. Semin Oncol. 2001;28:4–8.

    PubMed  Google Scholar 

  57. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23:4553–60.

    Article  CAS  PubMed  Google Scholar 

  58. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347–3.

    Article  CAS  PubMed  Google Scholar 

  59. Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284:1008–5.

    Article  CAS  PubMed  Google Scholar 

  60. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.

    Article  CAS  PubMed  Google Scholar 

  61. Rodel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25:110–7.

    Article  PubMed  Google Scholar 

  62. Van CE, Dicato M, Wils J, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer. 2002;38:1429–6.

    Article  Google Scholar 

  63. Baddi L, Benson 3rd A. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist. 2005;10:325–1.

    Article  PubMed  Google Scholar 

  64. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345:939–4.

    Google Scholar 

  65. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999–5.

    Article  CAS  PubMed  Google Scholar 

  66. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2.

    Article  CAS  PubMed  Google Scholar 

  67. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–5.

    Article  CAS  PubMed  Google Scholar 

  68. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–2.

    Article  CAS  PubMed  Google Scholar 

  69. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.

    Article  CAS  PubMed  Google Scholar 

  70. Lievre A, Bachet JB, Le CD, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–5.

    Article  CAS  PubMed  Google Scholar 

  71. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005;11:6650–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China

    Jianping Wang

Authors
  1. Jianping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianping Wang .

Editor information

Editors and Affiliations

  1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    Xinyu Qin

  2. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    Jianmin Xu

  3. Department of General Surgery, Zhongshan Hospital, Shanghai, China

    Yunshi Zhong

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Dordrecht and People's Medical Publishing House

About this chapter

Cite this chapter

Wang, J. (2017). Present Situation and Prospect of Diagnosis and Treatment of Colorectal Cancer. In: Qin, X., Xu, J., Zhong, Y. (eds) Multidisciplinary Management of Liver Metastases in Colorectal Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7755-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-7755-1_1

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-017-7753-7

  • Online ISBN: 978-94-017-7755-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation